Evommune, Inc. Shareholders' Equity
Evommune, Inc. (EVMN) had Shareholders' Equity of $277.59 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $277.59M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $304.56M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $205.57M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$183.14M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $277.59M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $304.56M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $205.57M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$183.14M 10-Q · filed 2025-12-11 |
| 2025-06-30 | -$171.23M 10-Q · filed 2026-08-06 |
| 2025-03-31 | -$158.24M 10-Q · filed 2026-08-06 |
| 2024-12-31 | -$144.24M 10-Q · filed 2026-08-06 |
| 2024-09-30 | -$122.53M 10-Q · filed 2025-12-11 |
| 2024-06-30 | -$107.03M 10-Q · filed 2025-12-11 |
| 2023-12-31 | -$77.71M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |